FibroBiologics, Inc. (FBLG) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 7, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FBLG SEC filings page.
This page shows FibroBiologics, Inc. (FBLG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported results depict a development-stage business whose operating losses consume cash and whose balance-sheet changes rely on financing.
The 2025 net loss of$18.6M closely matched operating cash outflow of$16.4M , indicating that reported losses largely represent current cash use rather than mainly non-cash accounting charges. With capital expenditures of only$262K , the cash requirement is primarily ongoing research and corporate operations, not heavy physical expansion.
Research and development increased from
The 2025 financing inflow of
Financial Health Signals
FibroBiologics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
FibroBiologics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
FibroBiologics, Inc. reported a net loss of $18.6M while operations used $16.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
FibroBiologics, Inc. reported an operating loss of $16.6M against $204K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
FibroBiologics, Inc.'s EBITDA was -$4.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is up 20.7%.
FibroBiologics, Inc. reported -$4.1M in net income in Q2 2026. This represents an increase of 11.6% from the same quarter a year earlier. Against the prior quarter it is up 17.7%.
Not reported for Q2 2026.
Cash & Balance Sheet
FibroBiologics, Inc. recorded an outflow of $3.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 21.6% from the same quarter a year earlier. Against the prior quarter it is up 24.6%.
FibroBiologics, Inc. held $3.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
FibroBiologics, Inc.'s ROE was -88.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 452.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 103.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
FibroBiologics, Inc. invested $1.7M in research and development in Q2 2026. This represents a decrease of 18.8% from the same quarter a year earlier. Against the prior quarter it is down 43.9%.
FibroBiologics, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
FBLG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.7M-18.8% | $3.0M+65.9% | N/A | $2.8M+129.9% | $2.0M+109.3% | $1.8M+85.4% | N/A | $1.2M+112.4% |
| SG&A Expenses | $2.4M-3.0% | $2.1M-23.1% | N/A | $2.2M+5.1% | $2.4M+8.9% | $2.8M+10.5% | N/A | $2.1M+44.4% |
| Operating Income | -$4.0M+10.2% | -$5.1M-11.9% | N/A | -$5.0M-50.3% | -$4.5M-39.3% | -$4.5M-31.3% | N/A | -$3.4M-63.4% |
| EBITDA | -$4.0M+10.5% | -$5.0M-11.7% | N/A | -$5.0M-50.1% | -$4.4M-39.0% | -$4.5M-31.1% | N/A | -$3.3M-62.5% |
| Interest Expense | $7K | $4K | N/A | $0-100.0% | $0-100.0% | $0-100.0% | N/A | $5K |
| Income Tax | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Net Income | -$4.1M+11.6% | -$5.0M-0.7% | N/A | -$5.8M-1055.6% | -$4.7M-618.7% | -$5.0M+41.3% | N/A | -$500K+77.2% |
| EPS (Basic) | -$0.66+72.6% | -$1.33+50.9% | -$0.03+66.7% | -$0.13-1200.0% | -$2.41-8133.3% | -$2.71-903.7% | -$0.09+74.3% | -$0.01+87.5% |
| EPS (Diluted) | -$0.66 | -$1.33 | -$0.03+66.7% | -$0.13-1200.0% | -$2.41 | -$2.71 | -$0.09+74.3% | -$0.01 |
| Diluted Shares (Avg) | 6M | 4M | N/A | 43M+28.5% | 2M | 2M | N/A | 34M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
FBLG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.9M-43.0% | $5.9M-48.0% | $9.6M-41.5% | $8.7M-16.5% | $13.9M+56.0% | $11.4M+0.2% | $16.4M+39.1% | $10.5M |
| Current Assets | $5.8M-42.5% | $2.9M-68.9% | $6.3M-55.4% | $5.2M-36.1% | $10.2M+56.4% | $9.3M+4.5% | $14.2M+54.4% | $8.2M |
| Cash & Equivalents | $3.5M-60.3% | $1.5M-82.9% | $4.9M-65.0% | $4.9M-37.8% | $8.8M+48.1% | $8.7M+6.2% | $14.0M+52.6% | $7.8M-27.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.3M-74.8% | $3.3M-63.2% | $3.5M-74.7% | $8.6M+11.5% | $13.0M+15.5% | $9.1M-40.5% | $13.7M+29.7% | $7.7M |
| Current Liabilities | $2.2M-79.8% | $1.8M-77.7% | $1.8M-86.2% | $6.7M+0.7% | $11.0M+8.2% | $8.2M-41.3% | $12.7M+38.6% | $6.7M |
| Non-Current Liabilities | $1.1M-48.2% | $1.5M+74.5% | $1.7M+73.2% | $1.9M+79.8% | $2.1M+78.5% | $865K-32.3% | $984K-29.0% | $1.1M |
| Total Equity | $4.6M+439.1% | $2.6M+10.6% | $6.2M+125.1% | $125K-95.4% | $860K+136.0% | $2.4M+160.8% | $2.7M+118.3% | $2.7M-74.0% |
| Retained Earnings | -$63.3M-40.2% | -$59.2M-46.1% | -$54.2M-52.5% | -$50.9M-57.1% | -$45.1M-41.4% | -$40.5M-23.4% | -$35.5M-45.8% | -$32.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
FBLG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M+17.4% | -$4.4M+17.3% | -$3.2M-2.9% | -$4.0M-52.4% | -$4.0M-104.6% | -$5.3M-23.4% | -$3.1M-91.9% | -$2.6M-128.8% |
| Depreciation & Amortization | $66K+10.0% | $66K+24.5% | $66K+40.4% | $65K+71.1% | $60K+62.2% | $53K+51.4% | $47K+51.6% | $38K+192.3% |
| Stock-Based Compensation | $707K-3.0% | $694K+26.0% | N/A | $704K+23.1% | $729K+25.9% | $551K+5.0% | N/A | $572K+30.0% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $6K-45.5% | $213K+222.7% | $43K+437.5% | $99K+4850.0% | $11K-97.3% |
| Free Cash Flow | -$3.3M+21.6% | -$4.4M+17.9% | -$3.2M+0.3% | -$4.0M-52.0% | -$4.2M-108.5% | -$5.3M-24.2% | -$3.2M-97.9% | -$2.6M-68.6% |
| Investing Cash Flow | $0+100.0% | $0+100.0% | $0+100.0% | -$6K+45.5% | -$213K-222.7% | -$43K-437.5% | -$99K-4850.0% | -$11K+97.3% |
| Financing Cash Flow | $5.3M+21.7% | $952K | $3.2M-65.8% | $0-100.0% | $4.4M+2643.6% | $0-100.0% | $9.3M | $4.5M+375.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
FBLG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -88.8%+452.8pp | -192.3%+19.0pp | N/A | -4622.4%-4604.1pp | -541.6% | -211.3% | N/A | -18.3%+2.5pp |
| Return on Assets | -51.9%-18.4pp | -84.2%-40.7pp | N/A | -66.1%-61.3pp | -33.5%-43.6pp | -43.5%+30.8pp | N/A | -4.8% |
| Current Ratio | 2.64+1.7x | 1.59+0.5x | 3.61+2.5x | 0.78-0.4x | 0.93+0.3x | 1.14+0.5x | 1.12+0.1x | 1.23 |
| Debt-to-Equity | 0.71-14.5x | 1.28-2.6x | 0.56-4.5x | 68.95+66.1x | 15.17 | 3.86 | 5.01-3.4x | 2.83 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| FibroBiologics, Inc. FBLG | FY2025 | N/A | -$18.6M | N/A | $7.9M | — |
| CytoMed Therapeutics Limited GDTC | FY2025 | $252K | -$3.1M | N/A | $12.1M | — |
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $1.9M | 42/100 |
| SeaStar Medical Holding Corporation ICU | FY2025 | $1.2M | -$12.2M | N/A | $15.6M | 44/100 |
| Lixte Biotechnology Holdings, Inc. LIXT | FY2025 | N/A | -$6.1M | N/A | $125.4M | — |
| Neuraxis, Inc. NRXS | FY2025 | $3.6M | -$7.8M | N/A | $89.8M | 44/100 |
Where FibroBiologics, Inc. Ranks
Frequently Asked Questions
Is FibroBiologics, Inc. profitable?
No, FibroBiologics, Inc. (FBLG) reported a net income of -$18.6M in fiscal year 2025.
What is FibroBiologics, Inc.'s EBITDA?
FibroBiologics, Inc. (FBLG) had EBITDA of -$16.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is FibroBiologics, Inc.'s return on equity (ROE)?
FibroBiologics, Inc. (FBLG) has a return on equity of -302.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is FibroBiologics, Inc.'s free cash flow?
FibroBiologics, Inc. (FBLG) recorded an outflow of $16.7M in free cash flow during fiscal year 2025. This represents a -37.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is FibroBiologics, Inc.'s operating cash flow?
FibroBiologics, Inc. (FBLG) recorded an outflow of $16.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are FibroBiologics, Inc.'s total assets?
FibroBiologics, Inc. (FBLG) had $9.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are FibroBiologics, Inc.'s capital expenditures?
FibroBiologics, Inc. (FBLG) invested $262K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does FibroBiologics, Inc. spend on research and development?
FibroBiologics, Inc. (FBLG) invested $7.4M in research and development during fiscal year 2025.
What is FibroBiologics, Inc.'s current ratio?
FibroBiologics, Inc. (FBLG) had a current ratio of 3.61 as of fiscal year 2025, which is generally considered healthy.
What is FibroBiologics, Inc.'s debt-to-equity ratio?
FibroBiologics, Inc. (FBLG) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is FibroBiologics, Inc.'s return on assets (ROA)?
FibroBiologics, Inc. (FBLG) had a return on assets of -193.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is FibroBiologics, Inc.'s P/E ratio?
FibroBiologics, Inc. (FBLG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.9M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is FibroBiologics, Inc.'s price-to-sales ratio?
FibroBiologics, Inc. (FBLG) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.9M as of Oct 7, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does FibroBiologics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, FibroBiologics, Inc. (FBLG) held $4.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.4M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is FibroBiologics, Inc.'s Piotroski F-Score?
FibroBiologics, Inc. (FBLG) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are FibroBiologics, Inc.'s earnings high quality?
FibroBiologics, Inc. (FBLG) reported a net loss of $18.6M while operations used $16.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can FibroBiologics, Inc. cover its interest payments?
FibroBiologics, Inc. (FBLG) reported an operating loss of $16.6M against $204K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.